ART-123 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
85	Idiopathic interstitial pneumonia	2

85. Idiopathic interstitial pneumonia

---

Clinical trials : 598 /  Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-JapicCTI-163326	01/5/2016	22/07/2016	Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis	Phase III clinical study of ART-123 for the treatment of acute exacerbation of idiopathic pulmonary fibrosis	Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF)	Intervention name : ART-123 INN of the intervention : thrombomodulin alfa Dosage And administration of the intervention : 380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy Control intervention name : Placebo Dosage And administration of the control intervention : Placebo by intravenous drip infusion in addition to standard of care steroid therapy	ASAHI KASEI PHARMA CORPORATION	NULL	recruiting	40	85	BOTH		Phase 3	NULL
2	NCT02739165 (ClinicalTrials.gov)	May 2016	1/4/2016	Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis	Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123	Idiopathic Pulmonary Fibrosis	Drug: ART-123;Drug: Placebo	Asahi Kasei Pharma Corporation	NULL	Completed	40 Years	85 Years	All	74	Phase 3	Japan